香港股市 將收市,收市時間:1 小時 15 分鐘

SkinBioTherapeutics plc (5KW.F)

Frankfurt - Frankfurt 延遲價格。貨幣為 EUR。
加入追蹤清單
0.08850.0000 (0.00%)
市場開市。 截至 09:24PM CEST。

SkinBioTherapeutics plc

The Core
Bath Lane Newcastle Helix
Newcastle upon Tyne NE4 5TF
United Kingdom
44 19 1495 7325
https://www.skinbiotherapeutics.com

版塊Healthcare
行業Biotechnology
全職員工11

高階主管

名稱頭銜支付行使價出生年份
Mr. Stuart John AshmanCEO & Executive Director430.89k1966
Mr. Manprit Singh RandhawaCFO, Secretary & Director303.61k1983
Laura BeyHead of Formulations
Ms. Melissa GreenwellGroup Financial Controller
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

公司管治

截至 無 止,SkinBioTherapeutics plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。